Stay updated on Pembrolizumab for Genomic Instability Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.

Latest updates to the Pembrolizumab for Genomic Instability Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded location sections for New Jersey and New York. Removed the separate 'New Jersey Locations' and 'New York Locations' blocks and updated the revision to v3.3.3.SummaryDifference0.3%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRemoved the 'Last known status' section and the entry for Eugenia Girda, MD, Rutgers Cancer Institute of New Jersey.SummaryDifference0.4%

- Check43 days agoChange DetectedThe page header/footer now displays Revision: v3.3.2, replacing the previous Revision: v3.2.0. This is a minor version change that does not affect the trial information or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedAdded a 'Results Submitted' status to the study page, replacing the previous 'No Results Posted' notice. This indicates that trial results have been submitted and are now available for review.SummaryDifference0.4%

- Check64 days agoChange DetectedThe updates appear to be formatting adjustments and minor text edits without altering core study details such as eligibility criteria or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check93 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference3%

Stay in the know with updates to Pembrolizumab for Genomic Instability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.